141 related articles for article (PubMed ID: 33243287)
1. Postoperative C-reactive protein kinetics predict postoperative complications in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis.
Asmar AE; Bendavides M; Moreau M; Hendlisz A; Deleporte A; Khalife M; Donckier V; Liberale G
World J Surg Oncol; 2020 Nov; 18(1):311. PubMed ID: 33243287
[TBL] [Abstract][Full Text] [Related]
2. Serum procalcitonin improves diagnosis of infectious complications after CRS/HIPEC.
Roth L; Eshmuminov D; Russo L; Laminger F; Kober F; Roka S; Lehmann K
World J Surg Oncol; 2023 Jan; 21(1):5. PubMed ID: 36631814
[TBL] [Abstract][Full Text] [Related]
3. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes.
Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL
Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
[No Abstract] [Full Text] [Related]
5. A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
Baumgartner JM; Kwong TG; Ma GL; Messer K; Kelly KJ; Lowy AM
Ann Surg Oncol; 2016 May; 23(5):1609-17. PubMed ID: 26678406
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy followed by hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastasis: a retrospective study of its safety and efficacy.
Zhou S; Jiang Y; Liang J; Pei W; Zhou Z
World J Surg Oncol; 2021 May; 19(1):151. PubMed ID: 34001125
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Laparoscopy in Patients With Peritoneal Carcinomatosis Is Safe and Does Not Delay Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy.
Hanna DN; Ghani MO; Hermina A; Mina A; Bailey CE; Idrees K; Magge D
Am Surg; 2022 Apr; 88(4):698-703. PubMed ID: 34732056
[TBL] [Abstract][Full Text] [Related]
8. High-grade postoperative complications affect survival outcomes of patients with colorectal Cancer peritoneal metastases treated with Cytoreductive surgery and Hyperthermic Intraperitoneal chemotherapy.
Zhou S; Feng Q; Zhang J; Zhou H; Jiang Z; Liu Z; Zheng Z; Chen H; Wang Z; Liang J; Pei W; Liu Q; Zhou Z; Wang X
BMC Cancer; 2021 Jan; 21(1):41. PubMed ID: 33413223
[TBL] [Abstract][Full Text] [Related]
9. Does early post-operative intraperitoneal chemotherapy (EPIC) for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) make a difference?
Tan GH; Ong WS; Chia CS; Tham CK; Soo KC; Teo MC
Int J Hyperthermia; 2016 May; 32(3):281-8. PubMed ID: 26862667
[TBL] [Abstract][Full Text] [Related]
10. Delayed presentation of major complications in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy following hospital discharge.
Bhagwandin SB; Naffouje S; Salti G
J Surg Oncol; 2015 Mar; 111(3):324-7. PubMed ID: 25557653
[TBL] [Abstract][Full Text] [Related]
11. Splenectomy Increases Postoperative Complications Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Dagbert F; Thievenaz R; Decullier E; Bakrin N; Cotte E; Rousset P; Vaudoyer D; Passot G; Glehen O
Ann Surg Oncol; 2016 Jun; 23(6):1980-5. PubMed ID: 26913716
[TBL] [Abstract][Full Text] [Related]
12. Systemic inflammatory markers for the detection of infectious complications and safe discharge after cytoreductive surgery and HIPEC.
Viyuela García C; Medina Fernández FJ; Arjona-Sánchez Á; Casado-Adam Á; Sánchez Hidalgo JM; Rufián Peña S; Briceño Delgado J
Surg Oncol; 2020 Sep; 34():163-167. PubMed ID: 32891323
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory biomarkers to predict postoperative infectious complications after cytoreductive surgery and HIPEC for peritoneal carcinomatosis.
Amroun K; Scholer V; Djerada Z; Renard Y; Bouche O; Rhaiem R; Kianmanesh R
Eur J Surg Oncol; 2022 Feb; 48(2):455-461. PubMed ID: 34565632
[TBL] [Abstract][Full Text] [Related]
14. Novel prognostic score for outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with metachronous peritoneal carcinomatosis.
Chin KM; Tan GHC; Chia CS; Ong JCA; Teo MCC
ANZ J Surg; 2020 Oct; 90(10):1958-1964. PubMed ID: 32159299
[TBL] [Abstract][Full Text] [Related]
15. Identifying the incidence of respiratory complications following diaphragmatic cytoreduction and hyperthermic intraoperative intraperitoneal chemotherapy.
Cascales Campos P; Martinez Insfran LA; Wallace D; Gil J; Gil E; Gonzalez Gil A; Martínez J; Alonso Romero JL; Gonzalez Sanchez R; Parrilla P
Clin Transl Oncol; 2020 Jun; 22(6):852-859. PubMed ID: 31392644
[TBL] [Abstract][Full Text] [Related]
16. Comparative Analysis of Postoperative Complications after Cytoreductive Surgery and HIPEC in Gastric Cancer.
Merboth F; Garcia S; V Renesse J; Distler M; Welsch T; Weitz J; Stange DE
Oncol Res Treat; 2022; 45(1-2):45-53. PubMed ID: 34844244
[TBL] [Abstract][Full Text] [Related]
17. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
[TBL] [Abstract][Full Text] [Related]
18. Postoperative time course and utility of inflammatory markers in patients with ovarian peritoneal carcinomatosis treated with neoadjuvant chemotherapy, cytoreductive surgery, and HIPEC.
Medina Fernández FJ; Muñoz-Casares FC; Arjona-Sánchez A; Casado-Adam A; Gómez-Luque I; Garcilazo Arismendi DJ; Thoelecke H; Rufián Peña S; Briceño Delgado J
Ann Surg Oncol; 2015 Apr; 22(4):1332-40. PubMed ID: 25234021
[TBL] [Abstract][Full Text] [Related]
19. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J
J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884
[TBL] [Abstract][Full Text] [Related]
20. Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin Increases the Risk of Postoperative Hemorrhagic Complications: Analysis of Predictive Factors.
Charrier T; Passot G; Peron J; Maurice C; Gocevska S; Quénet F; Eveno C; Pocard M; Goere D; Elias D; Ortega-Deballon P; Vaudoyer D; Cotte E; Glehen O
Ann Surg Oncol; 2016 Jul; 23(7):2315-22. PubMed ID: 26920385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
